Caribou Biosciences to Present at 43rd Annual J.P. Morgan Healthcare Conference
Caribou Biosciences to Present at 43rd Annual J.P. Morgan Healthcare Conference
BERKELEY, Calif., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced that Rachel Haurwitz, PhD, Caribou's president and chief executive officer, is scheduled to present a corporate update at the 43rd Annual J.P. Morgan Healthcare Conference on Thursday, January 16, 2025 at 10:30 am PST.
加利福尼亞州伯克利，2025年1月7日（環球新聞）-- Caribou Biosciences, Inc.（納斯達克：CRBU），一家領先的臨牀階段CRISPR基因組編輯生物製藥公司，今天宣佈，Caribou的總裁兼首席執行官Rachel Haurwitz博士，計劃在2025年1月16日（星期四）上午10:30（太平洋標準時間）在第43屆摩根大通醫療會議上進行企業更新報告。
For more information and a link to the live webcast, visit the Events page on Caribou's website. Webcasts will be available on the Caribou website for 30 days after the event.
有關更多信息和直播網絡研討會的鏈接，請訪問Caribou官網的活動頁面。事件結束後，網絡研討會將在Caribou官網上保留30天。
About Caribou's novel next-generation CRISPR platform
CRISPR genome editing uses easily designed, modular biological tools to make DNA changes in living cells. There are two basic components of Class 2 CRISPR systems: the nuclease protein that cuts DNA and the RNA molecule(s) that guide the nuclease to generate a site-specific, double-stranded break, leading to an edit at the targeted genomic site. CRISPR systems are capable of editing unintended genomic sites, known as off-target editing, which may lead to harmful effects on cellular function and phenotype. In response to this challenge, Caribou has developed CRISPR hybrid RNA-DNA guides (chRDNAs; pronounced "chardonnays") that direct substantially more precise genome editing compared to all-RNA guides. Caribou is deploying the power of its chRDNA technology to carry out high efficiency multiple edits, to develop CRISPR-edited therapies.
關於Caribou的新一代CRISPR平台
CRISPR基因編輯利用易於設計的模塊化生物工具對活細胞中的DNA進行修改。2類CRISPR系統有兩個基本元件：切割DNA的核酸酶蛋白和引導核酸酶生成特定部位雙鏈斷裂的RNA分子，這導致在目標基因組位點進行編輯。CRISPR系統能夠編輯意外的基因組位點，稱爲脫靶編輯，這可能對細胞功能和表現型產生有害影響。對此挑戰，Caribou開發了CRISPR雜化RNA-DNA引導（chRDNAs；發音爲「chardonnays」），與全 RNA 引導相比，這些引導實現了更精確的基因組編輯。Caribou正在利用其chRDNA技術的力量進行高效的多重編輯，以開發CRISPR編輯的療法。
About Caribou Biosciences, Inc.
Caribou Biosciences is a clinical-stage CRISPR genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company's genome-editing platform, including its Cas12a chRDNA technology, enables superior precision to develop cell therapies that are armored to potentially improve activity against disease. Caribou is advancing a pipeline of off-the-shelf cell therapies from its CAR-T platform as readily available treatments for patients with hematologic malignancies and autoimmune diseases. Follow us @CaribouBio and visit .
關於Caribou Biosciences, Inc.
Caribou生物科學是一家臨牀階段的CRISPR基因編輯生物製藥公司，致力於爲患有嚴重疾病的患者開發變革性療法。該公司的基因編輯平台，包括其Cas12a chRDNA技術，使得能夠以更高的精確度開發保護性細胞療法，以可能提高對抗疾病的活性。Caribou正在推進其CAR-t平台中的現成細胞療法管線，作爲可供患有血液惡性腫瘤和自身免疫疾病患者使用的治療方案。關注我們 @CaribouBio 並訪問。
Caribou Biosciences, Inc. contacts:
Investors:
Amy Figueroa, CFA
investor.relations@cariboubio.com
Caribou生物科學公司，聯繫方式：
投資者：
艾米·菲古羅亞，CFA
investor.relations@cariboubio.com
Media:
Peggy Vorwald, PhD
media@cariboubio.com
媒體：
佩吉·沃瓦爾德，博士
media@cariboubio.com
